Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AAN 2022 | Potential of anti-amyloid drugs for treating Alzheimer’s disease

Oscar López • 4 Apr 2022
AAN 2022
Alzheimer’s Disease Dementia Mild Cognitive Impairment Aducanumab Antibodies

Oscar López, MD, FAAN, University of Pittsburgh, Pittsburgh, PA, talks about the approval of aducanumab for treating patients with early-stage Alzheimer’s disease (AD) and discusses the potential of anti-amyloid drugs for treating early-stage AD. This interview took place at the American Academy of Neurology 2022 Congress in Seattle, WA.

More from Oscar López

1:02
Blood biomarkers for the diagnosis of Alzheimer's disease
Oscar López • 4 Apr 2022
1:26
Predictive factors of progression from mild cognitive impairment to dementia
Oscar López • 4 Apr 2022
1:35
Diagnosing mild cognitive impairment
Oscar López • 4 Apr 2022

Related Videos

2:33
Anti-amyloid therapy for Alzheimer's disease: beyond the 18-month mark
Dorota Religa • 22 Mar 2024
0:50
Will long-term anti-amyloid treatment show greater clinical benefit?
Dorota Religa • 22 Mar 2024
1:24
Digital frailty screening in dementia
Dorota Religa • 22 Mar 2024
4:19
Current projects from Alzheimer’s Disease International
Paola Barbarino • 23 Mar 2024
The content of VJDementia is intended for healthcare professionals